If Leronlimab is a viable option and prevents mortality and continues to prove that it prevents mortality in a high percentage of the patients that it is used on through the emergency IND, then I think it will be used and made available to as many US patients as possible. I think that with the current circumstances in the hospitals and country, it would be used for patients in the phase 2 clinical trial, and then the people that fall outside of the clinical trial, I believe they will put in a relaxed or broader emergency IND use.

If CytoDyn had 24,000 vials on hand and another 100,000 in production from Samsung, with a 6 week course, this could be used for roughly 20,666 patients.

At this time I do not think money would be the issue to secure the ramp up of leronlimab. I think with the given circumstances and the relaxed lending from banks, securing the product would not be an issue.